Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00066612 | S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | completed | Phase 2 | 45 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 2, 2012 | clinicaltrials |
| NCT00087295 | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium | terminated | Phase 2 | 6 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 2, 2012 | clinicaltrials |
| NCT00322699 | Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 22 | North Florida/South Georgia Veterans Health SystemOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT01551407 | Detection of Bladder Tumors After 30 Min Instillation of Hexvix | terminated | Phase 2 | 38 | PhotocureINDUSTRY | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00080795 | Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium | completed | Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2012 | clinicaltrials |
| NCT01265940 | Pazopanib and Vinflunine in Urothelial Cancer of the Bladder | completed | Phase 1 / Phase 2 | 5 | Prof. Dr. Thomas OttoOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00014144 | S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 8, 2012 | clinicaltrials |
| NCT00006026 | Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract | completed | Phase 2 | 21 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 24, 2012 | clinicaltrials |
| NCT00006351 | SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract | completed | Phase 2 | 34 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00023842 | BCG With or Without Mitomycin in Treating Patients With Bladder Cancer | completed | Phase 2 | 97 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00141531 | Phase II Trial of EOquin in High-risk Superficial Bladder Cancer | completed | Phase 2 | 53 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00003640 | Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 73 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 6, 2012 | clinicaltrials |
| NCT00003642 | Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 43 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Mar 6, 2012 | clinicaltrials |
| NCT01426126 | Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum | completed | Phase 2 | 37 | Asan Medical CenterOTHER | 1 | Dec 7, 2011 | clinicaltrials |
| NCT01215266 | Sorafenib in Urothelium Cancer of Bladder | terminated | Phase 2 | 98 | Association of Urologic Oncology (AUO)OTHER | 0 | Sep 8, 2011 | clinicaltrials |
| NCT00633204 | Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer | unknown | Phase 2 | 150 | Iwate Medical UniversityOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT00792025 | Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer | completed | Phase 2 | 80 | Institut CurieOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT01196403 | Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer | unknown | Phase 2 | 92 | Wales Cancer Trials UnitOTHER | 1 | Apr 1, 2011 | clinicaltrials |
| NCT00186277 | Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer | completed | Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 30, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00891748 | Safety Study on AdCD40L Gene Therapy for Bladder Cancer | completed | Phase 1 / Phase 2 | 12 | Uppsala UniversityOTHER | 1 | Jan 18, 2010 | clinicaltrials |
| NCT01000129 | Adaptive Planning in Bladder Cancer(APPLY) | unknown | Phase 2 | 32 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 22, 2009 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00816075 | Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | unknown | Phase 2 / Phase 3 | 40 | Bozyaka Training and Research HospitalOTHER | 1 | Feb 17, 2009 | clinicaltrials |
| NCT00818350 | Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer | unknown | Phase 1 / Phase 2 | 25 | Campania Younger Oncologists AssociationOTHER | 0 | Jan 7, 2009 | clinicaltrials |
| NCT00246974 | Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT | completed | Phase 2 | 125 | AstraZenecaINDUSTRY | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00006118 | Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer | unknown | Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 2 | Jul 24, 2008 | clinicaltrials |
| NCT00696579 | Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 64 | University Of PerugiaOTHER | 1 | Jun 12, 2008 | clinicaltrials |
| NCT00393809 | Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 18 | Hebrew University of JerusalemOTHER | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00490880 | Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer | completed | Phase 2 | 2 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00491114 | Intravesical Chemotherapy Treatment of Superficial Bladder Cancer | completed | Phase 2 | 8 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00343356 | Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder | completed | Phase 2 | 138 | LanZhou UniversityOTHER | 0 | Jun 22, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Nov 2, 2012source: clinicaltrials